MA43871A - Inhibition du lymphome 2 à cellules b (bcl -2) et des protéines apparentées - Google Patents
Inhibition du lymphome 2 à cellules b (bcl -2) et des protéines apparentéesInfo
- Publication number
- MA43871A MA43871A MA043871A MA43871A MA43871A MA 43871 A MA43871 A MA 43871A MA 043871 A MA043871 A MA 043871A MA 43871 A MA43871 A MA 43871A MA 43871 A MA43871 A MA 43871A
- Authority
- MA
- Morocco
- Prior art keywords
- bcl
- inhibition
- cell lymphoma
- related proteins
- proteins
- Prior art date
Links
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 title 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 title 1
- 208000003950 B-cell lymphoma Diseases 0.000 title 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662277248P | 2016-01-11 | 2016-01-11 | |
| US201762444168P | 2017-01-09 | 2017-01-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43871A true MA43871A (fr) | 2018-11-21 |
Family
ID=59312078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043871A MA43871A (fr) | 2016-01-11 | 2017-01-11 | Inhibition du lymphome 2 à cellules b (bcl -2) et des protéines apparentées |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3402485A1 (fr) |
| JP (1) | JP2019501225A (fr) |
| AU (1) | AU2017206731A1 (fr) |
| MA (1) | MA43871A (fr) |
| WO (1) | WO2017123616A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019139902A1 (fr) | 2018-01-10 | 2019-07-18 | Zeno Royalties & Milestones, LLC | Composés benzamide |
| US12383508B2 (en) | 2018-09-19 | 2025-08-12 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| CN110143941B (zh) * | 2019-06-04 | 2021-05-25 | 北京四环制药有限公司 | 一种巴罗萨韦玛波酯中间体的合成方法 |
| WO2021007303A1 (fr) * | 2019-07-10 | 2021-01-14 | Recurium Ip Holdings, Llc | Formulation de nanoparticules d'inhibiteur de la bcl-2 |
| US20230025865A1 (en) * | 2019-12-11 | 2023-01-26 | The Regents Of The University Of Michigan | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS |
| MX2024000795A (es) * | 2021-07-16 | 2024-03-25 | Celator Pharmaceuticals Inc | Metodos para preparar formulaciones liposomales. |
| WO2023190709A1 (fr) * | 2022-03-31 | 2023-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Composition de liposomes et composition pharmaceutique contenant des liposomes |
| WO2024012557A1 (fr) * | 2022-07-15 | 2024-01-18 | Berrybio (Hong Kong) Limited | Agents de dégradation de protéines anti-apoptotiques de la famille bcl-2, compositions pharmaceutiques et applications thérapeutiques |
| AU2024294424A1 (en) * | 2023-07-14 | 2025-11-20 | Jazz Pharmaceuticals Therapeutics, Inc. | Methods of use of a liposomal composition comprising an atr inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5043164A (en) * | 1989-01-17 | 1991-08-27 | The University Of Tennessee Research Corporation | Blood-stable, cholesterol-free liposomes |
| CA2821167C (fr) * | 2004-05-03 | 2016-06-28 | Merrimack Pharmaceuticals, Inc. | Liposomes pour l'administration de drogues contenant des polyols anioniques ou des sucres anioniques |
| CA2606147C (fr) * | 2005-05-12 | 2011-07-05 | Abbott Laboratories | Promoteurs d'apoptose |
| JP5277168B2 (ja) * | 2006-09-05 | 2013-08-28 | アボット・ラボラトリーズ | 血小板過剰を治療するｂｃｌインヒビター |
| BR112012005343A2 (pt) * | 2009-09-10 | 2016-03-22 | Novartis Ag | sulfonamidas como inibidores de proteínas da família bcl-2 para o tratamento de câncer |
-
2017
- 2017-01-11 MA MA043871A patent/MA43871A/fr unknown
- 2017-01-11 EP EP17738848.5A patent/EP3402485A1/fr not_active Withdrawn
- 2017-01-11 WO PCT/US2017/012992 patent/WO2017123616A1/fr not_active Ceased
- 2017-01-11 JP JP2018554661A patent/JP2019501225A/ja active Pending
- 2017-01-11 AU AU2017206731A patent/AU2017206731A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017123616A1 (fr) | 2017-07-20 |
| EP3402485A1 (fr) | 2018-11-21 |
| AU2017206731A1 (en) | 2018-08-02 |
| JP2019501225A (ja) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43871A (fr) | Inhibition du lymphome 2 à cellules b (bcl -2) et des protéines apparentées | |
| IL281568A (en) | Collagen-localized immunomodulatory molecules and methods thereof | |
| EP4003319A4 (fr) | Inhibiteurs de hdac6 et leurs utilisations | |
| MA50860A (fr) | Récepterus chimériques d'antigène contre l'antigène de maturation des cellules b et polynucleotides codants | |
| LT3788042T (lt) | Bcl-2 inhibitoriai | |
| EP3836561C0 (fr) | Unité haut-parleur et dispositif haut-parleur | |
| PL3694529T3 (pl) | Trójswoiste białka i sposoby zastosowania | |
| DK3737765T4 (da) | Forstærkede immunceller med dobbelt shrna og sammensætning dermed | |
| IL282090A (en) | Tyk2 inhibitors and uses thereof | |
| DK3578547T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
| MA42819A (fr) | Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae | |
| EP3399956A4 (fr) | Compositions cosmétiques contenant des céramides et du cholestérol | |
| MA45270A (fr) | Compositions d'oligonucléotides et procédés associés | |
| IL280655A (en) | Particles containing coloring agents and methods of using the same | |
| HUE052468T2 (hu) | Arginázgátlók és terápiás alkalmazásaik | |
| DK3697405T3 (da) | Ny mek-inhibitor til behandlingen af virale og bakterielle infektioner | |
| EP3532092A4 (fr) | Immunoglobulines et utilisations de celles-ci | |
| EP3893945A4 (fr) | Esters cromoglycique et leurs utilisations | |
| EP3635000A4 (fr) | Manabodies et procédés d'utilisation | |
| EP3666729A4 (fr) | Composition contenant du nano-soufre et application associée | |
| EP3442505A4 (fr) | Associations pour le traitement de néoplasmes à l'aide du ciblage de cellules inactives et d'inhibiteurs de l'egfr | |
| EP3849664C0 (fr) | Composés phénoxy-pyridyl-pyrimidine et méthodes d'utilisation associées | |
| EP3412273A4 (fr) | Matiériau de dévitalisation dentaire et kit de dévitalisation dentaire | |
| EP3706947A4 (fr) | Étalonnage d'entrelacement et procédés d'utilisation de celui-ci | |
| EP3704104A4 (fr) | Inhibiteurs d'irak4 et leurs utilisations |